Atrovent hfa and Adempas drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Atrovent hfa (ipratropium bromide) and Adempas (riociguat). Common drug interactions include appetite disorder among females and pulmonary hypertension among males.

The phase IV clinical study analyzes what interactions people have when they take Atrovent hfa and Adempas. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Atrovent hfa?

Atrovent hfa has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 2,440 Atrovent hfa users. Check the latest studies of Atrovent hfa.

What is Adempas?

Adempas has active ingredients of riociguat. eHealthMe is studying from 29,741 Adempas users. Check the latest studies of Adempas.



On Jul, 26, 2026

12 people who take Atrovent hfa and Adempas together, and have interactions are studied.

Atrovent hfa and Adempas drug interactions.

What are the common drug interactions of Atrovent Hfa and Adempas, by gender? *:

female:

  1. Appetite disorder (abnormal eating habits)
  2. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  3. Weight decreased
  4. Breast cancer
  5. Cardiac disorder
  6. Chest pain
  7. Death
  8. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  9. Dyspepsia (indigestion)
  10. Dyspnoea (difficult or laboured respiration)

male:

  1. Pulmonary hypertension (increase in blood pressure in the lung artery)
  2. Fluid overload (too much fluid in the blood)
  3. Contusion (a type of hematoma of tissue in which capillaries)
  4. Diarrhoea
  5. Gastritis (inflammation of stomach)
  6. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  7. Hospitalisation
  8. Hypoxia (low oxygen in tissues)
  9. Lung disorder (lung disease)
  10. Oedema (fluid collection in tissue)

What are the common drug interactions of Atrovent Hfa and Adempas, by age (0-1 to 60+)? *:

0-1:

  1. Pneumonia
  2. Pyrexia (fever)
  3. Rhinovirus infection
  4. Pulmonary hypertension (increase in blood pressure in the lung artery)
  5. Acute respiratory distress syndrome
  6. Contusion (a type of hematoma of tissue in which capillaries)
  7. Gastritis (inflammation of stomach)
  8. Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
  9. Hospitalisation
  10. Hypoxia (low oxygen in tissues)

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Appetite disorder (abnormal eating habits)
  2. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  3. Weight decreased

40-49:

  1. Cardiac disorder
  2. Chest pain
  3. Death
  4. Dyspepsia (indigestion)
  5. Dyspnoea (difficult or laboured respiration)
  6. Dyspnoea exertional (breathlessness or shortness of breath)
  7. Ear discomfort
  8. Flushing (the warm, red condition of human skin)
  9. Headache (pain in head)
  10. Heart rate increased

50-59:

n/a

60+:

  1. Fluid overload (too much fluid in the blood)
  2. Hypotension (abnormally low blood pressure)
  3. Malaise (a feeling of general discomfort or uneasiness)
  4. Renal disorder (kidney disease)
  5. Right ventricular failure (right half of the heart fails to work)
  6. Pulmonary hypertension (increase in blood pressure in the lung artery)
  7. Diarrhoea
  8. Oedema (fluid collection in tissue)
  9. Pulmonary embolism (blockage of the main artery of the lung)

What are the existing conditions these people have? *

  1. Pulmonary Hypertension (increase in blood pressure in the lung artery): 6 people, 50.00%
  2. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 5 people, 41.67%
  3. Pulmonary Embolism (blockage of the main artery of the lung): 3 people, 25.00%
  4. Premature Baby: 1 person, 8.33%
  5. Mitochondrial Enzyme Deficiency (lack of mitrocondrial enzyme): 1 person, 8.33%
  6. Metabolic Disorder (an abnormal function and pattern of body fat. insulin resistance refers to the diminished ability of cells to respond to the action of insulin in promoting the transport of the sugar glucose, from blood into muscles and other tissues): 1 person, 8.33%
  7. Low Birth Weight Baby: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Atrovent hfa and Adempas?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Atrovent hfa and Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Atrovent hfa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Adempas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Atrovent hfa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Adempas and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ipratropium bromide and riociguat (the active ingredients of Atrovent hfa and Adempas, respectively), and Atrovent hfa and Adempas (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: